Liver And Kidney Tests For TRT: A Monitoring Guide

The liver and kidney tests used in TRT monitoring come from a single lab order called the Comprehensive Metabolic Panel (CMP). A standard CMP covers 6 liver markers (AST, ALT, ALP, bilirubin, albumin, total protein) and 3 kidney markers (creatinine, BUN, eGFR), along with electrolytes and fasting glucose. The Endocrine Society and the AUA name testosterone, hematocrit, and first-year prostate-risk assessment as the core on-treatment labs (Bhasin et al., 2018; Mulhall et al., 2018). Liver and kidney markers enter through FDA label language, TRAVERSE trial data, and clinical judgment, not through a society-mandated quarterly schedule. Men on TRT who need liver and kidney monitoring alongside their hormone labs can order direct-pay lab testing through Marek Diagnostics.

A Comprehensive Metabolic Panel is a 14-marker blood test that screens liver enzymes, kidney filtration, electrolytes, and fasting glucose from a single blood draw. During TRT, a CMP at baseline gives the prescribing provider a creatinine and ALT to compare against later values, and a low threshold to repeat the panel when symptoms or comorbidities call for it.

What Liver and Kidney Tests Does TRT Monitoring Include?

A standard CMP captures liver and kidney function in 1 draw. It covers 3 categories that matter for men on testosterone.

Liver-related markers include AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), total bilirubin, albumin, and total protein. Together these reflect liver cell health, bile flow, and the liver's ability to produce proteins. ALT is the most liver-specific of the group.

Kidney-related markers include creatinine, BUN (blood urea nitrogen), and eGFR (estimated glomerular filtration rate, calculated from creatinine). These track how well the kidneys filter waste.

The remaining CMP markers, sodium, potassium, chloride, CO2, calcium, and fasting glucose, round out the metabolic picture. Testosterone labels warn that androgens may promote sodium and water retention, so electrolyte status has clinical relevance for men with preexisting cardiac or renal disease.

A CMP is available as a single-order test or as part of a bundled lab panel that adds testosterone, CBC, and other markers.

Liver Risk Depends on the Testosterone Formulation

Not all testosterone formulations carry the same liver profile. The answer splits along 1 molecular line, and NIH's LiverTox database is the primary source for the distinction (NIDDK LiverTox).

The 17-alpha-alkylated oral androgens (methyltestosterone and related anabolic agents) are the molecular class associated with the classic hepatic warnings. LiverTox links this class to cholestasis, peliosis hepatis, hepatic adenomas, and hepatocellular carcinoma. These are older agents and are not first-line replacement therapy.

Injectable esters (cypionate, enanthate) and transdermal gels sit in a different category. Based on available evidence, LiverTox states that cholestasis has not been described with unmodified testosterone given by injection or transdermal patch at standard replacement doses. C-17-beta esters are only rarely implicated, and current product labels note these formulations are "not known to produce" the hepatic events linked to methyltestosterone.

Modern oral testosterone undecanoate (Jatenzo, Tlando, Kyzatrex) is not 17-alpha-alkylated. It absorbs through intestinal lymph, reducing first-pass liver exposure compared with methyltestosterone. Pooled trial data showed no clinically meaningful liver toxicity signal, though labels still reprint the older methyltestosterone warning language and instruct men to report jaundice.

That molecular distinction is the reason a man on injectable cypionate at a replacement dose may not require the same liver-monitoring frequency as someone using an older alkylated oral. FDA labels still tell all testosterone users to report signs of hepatic dysfunction. A baseline ALT from the CMP gives the provider a reference point, so a later change can be evaluated against the starting value rather than guessed at.

How Does TRT Affect Kidney Function?

The TRAVERSE trial is the primary source for the kidney signal in TRT. In the trial's enrolled population, 5,246 men ages 45-80 who met laboratory and clinical criteria for hypogonadism with preexisting cardiovascular disease or high CV risk received testosterone gel 1.62% or placebo. The primary cardiac endpoint was neutral (MACE 7.0% vs. 7.3%; HR 0.96, 95% CI 0.78-1.17). In the same trial, acute kidney injury occurred in 2.3% on testosterone vs. 1.5% on placebo (P = 0.04). Atrial fibrillation was 3.5% vs. 2.4%, and pulmonary embolism was 0.9% vs. 0.5% (Lincoff et al., 2023). TRAVERSE enrolled men with preexisting cardiovascular disease or multiple CV risk factors, so these rates may not generalize to lower-risk men on TRT. Updated 2025 gel labels now list those TRAVERSE adverse reactions, including the AKI finding (FDA, 2025).

Labels also warn that androgens may promote sodium and water retention, a risk that is more serious in men with preexisting cardiac, renal, or hepatic disease.

A detail most TRT monitoring articles skip: a rising creatinine on testosterone doesn't automatically mean kidney injury. Testosterone can increase muscle mass. Muscle produces creatinine. A higher creatinine from muscle gain may lower eGFR on paper without a matching drop in true kidney filtration. A provider separating that artifact from TRAVERSE-style AKI would look at BUN, check for edema and changes in urine output, review NSAIDs and other medications, and consider cystatin C if available. Cystatin C is not on a standard CMP but can be added when the creatinine picture is unclear.

Liver and Kidney Labs in the TRT Monitoring Schedule

The society-mandated core labs are testosterone, hematocrit, and prostate-risk assessment (PSA for men over 40). The Endocrine Society recommends checking testosterone and hematocrit at 3-6 months after starting or adjusting therapy, at 12 months, and annually once stable (Bhasin et al., 2018). The AUA recommends testosterone testing every 6-12 months (Mulhall et al., 2018). A CBC with differential tracks hematocrit and hemoglobin. Testosterone testing confirms hormone levels are in range.

The CMP, and with it the liver and kidney markers, sits in a different tier. Neither guideline mandates a fixed CMP interval for every man on an FDA-approved ester, gel, or modern oral formulation. A CMP at baseline is reasonable, because it catches preexisting liver or kidney disease that changes risk and drug selection. Repeating it is indication-driven, not calendar-driven.

Indications to retest liver and kidney markers include jaundice or dark urine, right-upper-quadrant abdominal pain, sudden swelling or edema, a creatinine jump without a clear explanation (new medication, dehydration), a new hepatotoxic drug starting alongside testosterone, known CKD, cirrhosis, or heart failure, and a TRAVERSE-like CV/renal risk profile. Men who want to customize individual biomarker testing can add or remove markers based on their provider's assessment.

Consumer articles that list "LFT and CMP every 3 months" are not citing society text. Current society guidelines don't require quarterly liver panels for men on FDA-approved injectable or transdermal testosterone. A baseline CMP and a low threshold to repeat it when clinical indicators arise is the evidence-based middle ground.

Before and After the TRT Blood Draw

A fasting specimen (8 hours minimum, water only) is preferred because the CMP includes fasting glucose. Morning collection between 7 and 10 AM is standard for testosterone accuracy, since testosterone follows a circadian rhythm and peaks early in the day. An afternoon draw can read lower in the same person. Marek Diagnostics offers guidance on preparing for blood work.

For injectable testosterone, the draw should happen at trough (before the next injection) unless a provider requests peak testing (24-48 hours after the injection). Gel users don't have the same peak-trough swings, so morning collection on any day works. The liver and kidney markers on the CMP aren't affected by injection timing.

A phlebotomist draws blood from a vein, usually at the inside of the elbow. The visit takes 10-15 minutes. 1 sample is collected and split across the panel's test categories at the lab. Results typically return in 1-3 business days. Multi-component panels sometimes post in stages; the CBC may appear before the CMP or testosterone results. Men who want to see how the process works from order to results can visit the Marek Diagnostics walkthrough.

Reading Liver and Kidney Results on TRT

A mildly high ALT or AST doesn't always point to a testosterone problem. Intense resistance training, alcohol use, and fatty liver disease unrelated to TRT can all shift liver enzymes. Clinical interpretation depends on the trend across multiple draws, not a single result. Markedly high liver enzymes, especially alongside bilirubin changes, need prompt follow-up. For men on injectable esters or gels, based on available evidence, cholestasis has not been described at standard replacement doses for these formulations.

For kidney markers, a creatinine rise during TRT has 2 possible explanations: more muscle mass producing more creatinine (a lab artifact, not kidney damage), or a true reduction in kidney filtration. TRAVERSE reported higher acute kidney injury with testosterone gel (2.3% vs. 1.5%) in a high-CV-risk population, so the number deserves clinical attention in men with diabetes, heart failure, or concurrent use of NSAIDs, diuretics, or SGLT2 inhibitors (Lincoff et al., 2023). Individual risk factors and clinical context should guide how a provider interprets a creatinine change.

Testosterone and estradiol results from the same panel give the provider a picture of hormone response and aromatization balance. The AUA identifies a hematocrit at or above 54% as a threshold that may prompt intervention, based on the individual's clinical picture (Mulhall et al., 2018). Men who use testosterone-related lab panels through Marek Diagnostics can add markers based on their provider's assessment. Liver and kidney markers on a TRT blood panel give the prescribing provider the data needed to make informed adjustments to therapy.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

What liver tests are needed on TRT?

The Endocrine Society's monitoring plan names testosterone, hematocrit, and first-year prostate-risk assessment as the core labs, not a standing liver-enzyme schedule. FDA labels tell men on testosterone to report jaundice, and some older labels reference periodic liver testing because of 17-alpha-alkylated androgens. A baseline CMP that includes AST, ALT, ALP, and bilirubin is reasonable, with repeat testing driven by symptoms or a change in the clinical picture.

Does injectable testosterone damage the liver?

Based on available evidence, NIDDK's LiverTox database states that cholestasis has not been described with unmodified injectable or transdermal testosterone at standard replacement doses. The hepatic warnings on current labels originate from 17-alpha-alkylated oral androgens such as methyltestosterone, a different molecular class. Injectable esters (cypionate, enanthate) are C-17-beta compounds with a lower liver-risk profile.

What kidney tests are needed during TRT?

Creatinine, BUN, and eGFR are the kidney markers on a standard CMP. These aren't society-mandated at a fixed interval for TRT, but a baseline value gives the provider a reference point. Cystatin C can be added when creatinine rises and the provider needs to separate a muscle-mass artifact from a true drop in kidney filtration.

Can TRT cause kidney problems?

The TRAVERSE trial reported acute kidney injury in 2.3% of men receiving testosterone gel vs. 1.5% on placebo in a population with preexisting cardiovascular disease or high CV risk, along with higher rates of atrial fibrillation and pulmonary embolism, while the primary cardiac endpoint was neutral (MACE 7.0% vs. 7.3%). The 2025 gel labels now list those adverse reactions. Men with preexisting renal disease, heart failure, or concurrent use of NSAIDs may warrant more frequent CMP monitoring based on their individual risk profile.

Why does creatinine rise on testosterone therapy?

Testosterone can increase muscle mass. Muscle tissue produces creatinine. A rise in serum creatinine from muscle gain may lower eGFR on paper without a matching drop in true kidney filtration. A provider distinguishing that lab artifact from TRAVERSE-style acute kidney injury would review BUN, check for edema, evaluate urine output, and consider cystatin C. A creatinine jump with symptoms (swelling, reduced urine, fatigue) needs investigation, not reassurance.

How often should men on TRT retest liver and kidney markers?

The Endocrine Society and the AUA do not set a fixed CMP interval for TRT. A baseline CMP before starting therapy is reasonable. Repeat testing is driven by clinical indicators: jaundice, dark urine, sudden edema, a creatinine jump, a new hepatotoxic drug, or preexisting liver, kidney, or heart disease. Current society guidelines don't require quarterly liver panels for men on FDA-approved injectables or gels with no risk factors and no symptoms.

References

• FDA Drug Safety Communication: Class-wide labeling changes for testosterone products. February 28, 2025.

• J Clin Endocrinol Metab. 2018;103(5):1715-1744.

• J Urol. 2018;200(2):423-432.

• LiverTox: Androgenic Steroids. National Institute of Diabetes and Digestive and Kidney Diseases.

• N Engl J Med. 2023;389:107-117.